

Integrated analysis for treatment scheme of sodium-glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study

Li Fang^{1,2,3,4,5}, Guangpu Li^{1,2,3,4,5}, Jingjing Ren^{1,2,3,4,5}, Jiayu Duan^{1,2,3,4,5*}, Jiancheng Dong^{5*} and Zhangsuo Liu^{1,2,3,4*}

¹Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

²Research Institute of Nephrology, Zhengzhou University, Zhengzhou, China

³Henan Province Research Center For Kidney Disease, Zhengzhou, China


⁴Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China

⁵Clinical Research Center of Big-data, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

*Correspondence to: Jiayu Duan, jyduan@hotmail.com

Jiancheng Dong, fccjcdong@zzu.edu.cn

Zhangsuo Liu, zhangsuoliu@zzu.edu.cn



Supplementary Fig S1. Subgroup analyses in eGFR ≥ 45 ml/min/1.73m² patients.

Abbreviations: SGLT2i, sodium-glucose cotransporter 2 inhibitor; BMI, body mass index; HbA1c, glycosylated hemoglobin; UACR, urine albumin creatine ratio; CVD, cardiovascular disease; ACEI/ARBs, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; eGFR, estimated glomerular filtration rate.